Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed gastric or gastroesophageal junction adenocarcinoma * Locally advanced unresectable or metastatic disease * Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10mm by spiral CT scan * Bone metastases, ascites, or pleural effusions are not considered measurable disease * Evaluable disease must be present outside previously irradiated field * No CNS or brain metastases PATIENT CHARACTERISTICS: Age * 18 and over Performance status * SWOG 0-1 Life expectancy * Not specified Hematopoietic * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 mg/dL * No evidence of bleeding diathesis or coagulopathy Hepatic * AST and ALT ≤ 2.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 2.5 times ULN * Bilirubin ≤ ULN * INR \< 1.5 Renal * Creatinine \< 2.0 mg/dL * Urine protein:creatinine ratio \< 1.0 Cardiovascular * No history of deep venous thrombosis requiring anticoagulation * No active angina * No myocardial infarction within the past year * No cerebrovascular accident within the past year * No uncontrolled hypertension (systolic blood pressure \[BP\] \> 170 mm Hg and/or diastolic BP \> 100 mm Hg) despite medical management Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after completion of study treatment * No peripheral neuropathy \> grade 1 * No history of allergy to any of the study drugs or drugs formulated with polysorbate 80 * No known HIV infection * No active peptic ulcer disease * No serious non-healing wound, ulcer, or bone fracture * No unresolved bacterial infection requiring antibiotics * No other active malignancy within the past 3 years except for cancers that have been treated with a curative intent PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent immunotherapy Chemotherapy * No prior chemotherapy for gastric cancer unless disease relapsed \> 6 months after completion of non-taxane adjuvant chemotherapy * No other concurrent chemotherapy Endocrine therapy * Not specified Radiotherapy * See Disease Characteristics * At least 3 weeks since radiotherapy Surgery * At least 4 weeks since prior surgery or open biopsy (except indwelling venous catheter placement) * No concurrent surgery Other * At least 4 weeks since prior and no concurrent participation in another experimental drug trial * No concurrent full-dose anticoagulation * No concurrent experimental drugs